398 related articles for article (PubMed ID: 24524339)
1. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
4. Purine analogs in the treatment of chronic lymphocytic leukemia.
Pott C; Hiddemann W
Leukemia; 1997 Apr; 11 Suppl 2():S25-8. PubMed ID: 9178834
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Juliusson G; Liliemark J
Ann Oncol; 1996 Apr; 7(4):373-9. PubMed ID: 8805929
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine versus chlorambucil: is the debate over?
Rai KR; Hollweg A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S7-9. PubMed ID: 22035752
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
13. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Eichhorst BF; Busch R; Stilgenbauer S; Stauch M; Bergmann MA; Ritgen M; Kranzhöfer N; Rohrberg R; Söling U; Burkhard O; Westermann A; Goede V; Schweighofer CD; Fischer K; Fink AM; Wendtner CM; Brittinger G; Döhner H; Emmerich B; Hallek M;
Blood; 2009 Oct; 114(16):3382-91. PubMed ID: 19605849
[TBL] [Abstract][Full Text] [Related]
14. Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
Robak T; Błoński JZ; Kasznicki M
Leuk Lymphoma; 2001 May; 41(5-6):545-57. PubMed ID: 11378572
[TBL] [Abstract][Full Text] [Related]
15. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky D; Richards S; Matutes E; Oscier D; Dyer M; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P; ;
Lancet; 2007 Jul; 370(9583):230-239. PubMed ID: 17658394
[TBL] [Abstract][Full Text] [Related]
16. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Robak T; Kasznicki M
Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
[TBL] [Abstract][Full Text] [Related]
17. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
Leporrier M
Hematol J; 2004; 5 Suppl 1():S10-9. PubMed ID: 15079149
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Ayyildiz O; Isikdogan A; Bolaman Z; Muftuoglu E
Saudi Med J; 2004 Dec; 25(12):2054-6. PubMed ID: 15711709
[No Abstract] [Full Text] [Related]
19. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
Hematol Cell Ther; 1999 Jun; 41(3):127-36. PubMed ID: 10456443
[No Abstract] [Full Text] [Related]
[Next] [New Search]
